JP2023534043A - ポリヌクレオチドを縮小サイズの脂質ナノ粒子に封入する方法及びその新規製剤 - Google Patents

ポリヌクレオチドを縮小サイズの脂質ナノ粒子に封入する方法及びその新規製剤 Download PDF

Info

Publication number
JP2023534043A
JP2023534043A JP2023502945A JP2023502945A JP2023534043A JP 2023534043 A JP2023534043 A JP 2023534043A JP 2023502945 A JP2023502945 A JP 2023502945A JP 2023502945 A JP2023502945 A JP 2023502945A JP 2023534043 A JP2023534043 A JP 2023534043A
Authority
JP
Japan
Prior art keywords
lipid
pharmaceutical composition
cedna
alkyl
itr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023502945A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534043A5 (cg-RX-API-DMAC7.html
Inventor
ノラン ギャラガー,
マシュー ジー. スタントン,
グレゴリー ファインスタイン,
Original Assignee
ジェネレーション バイオ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネレーション バイオ カンパニー filed Critical ジェネレーション バイオ カンパニー
Publication of JP2023534043A publication Critical patent/JP2023534043A/ja
Publication of JP2023534043A5 publication Critical patent/JP2023534043A5/ja
Priority to JP2026017935A priority Critical patent/JP2026074198A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023502945A 2020-07-17 2021-07-16 ポリヌクレオチドを縮小サイズの脂質ナノ粒子に封入する方法及びその新規製剤 Pending JP2023534043A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026017935A JP2026074198A (ja) 2020-07-17 2026-02-05 ポリヌクレオチドを縮小サイズの脂質ナノ粒子に封入する方法及びその新規製剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063053274P 2020-07-17 2020-07-17
US63/053,274 2020-07-17
US202163194620P 2021-05-28 2021-05-28
US63/194,620 2021-05-28
PCT/US2021/042033 WO2022016089A2 (en) 2020-07-17 2021-07-16 Methods for encapsulating polynucleotides into reduced sizes of lipid nanoparticles and novel formulation thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026017935A Division JP2026074198A (ja) 2020-07-17 2026-02-05 ポリヌクレオチドを縮小サイズの脂質ナノ粒子に封入する方法及びその新規製剤

Publications (2)

Publication Number Publication Date
JP2023534043A true JP2023534043A (ja) 2023-08-07
JP2023534043A5 JP2023534043A5 (cg-RX-API-DMAC7.html) 2024-07-24

Family

ID=79555025

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023502945A Pending JP2023534043A (ja) 2020-07-17 2021-07-16 ポリヌクレオチドを縮小サイズの脂質ナノ粒子に封入する方法及びその新規製剤
JP2026017935A Pending JP2026074198A (ja) 2020-07-17 2026-02-05 ポリヌクレオチドを縮小サイズの脂質ナノ粒子に封入する方法及びその新規製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026017935A Pending JP2026074198A (ja) 2020-07-17 2026-02-05 ポリヌクレオチドを縮小サイズの脂質ナノ粒子に封入する方法及びその新規製剤

Country Status (10)

Country Link
US (1) US20230320993A1 (cg-RX-API-DMAC7.html)
EP (1) EP4181948A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023534043A (cg-RX-API-DMAC7.html)
KR (1) KR20230052895A (cg-RX-API-DMAC7.html)
CN (1) CN116437964A (cg-RX-API-DMAC7.html)
AU (1) AU2021307952A1 (cg-RX-API-DMAC7.html)
CA (1) CA3186033A1 (cg-RX-API-DMAC7.html)
IL (1) IL299896A (cg-RX-API-DMAC7.html)
MX (1) MX2023000806A (cg-RX-API-DMAC7.html)
WO (1) WO2022016089A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024522692A (ja) * 2021-06-14 2024-06-21 ジェネレーション バイオ カンパニー カチオン性脂質及びその組成物
JP2024538582A (ja) * 2021-09-28 2024-10-23 セキラス インコーポレイテッド イオン化可能なカチオン性化合物

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
KR20190064600A (ko) 2016-09-23 2019-06-10 듀크 유니버시티 Lcst 거동을 갖는 비구조화된 비-반복적 폴리펩티드
EP3658168A4 (en) 2017-06-30 2021-07-14 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-RESPONDING BIOPOLYMER NETWORKS
WO2019147954A1 (en) 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
WO2019213150A1 (en) 2018-04-30 2019-11-07 Duke University Stimuli-responsive peg-like polymer-based drug delivery platform
WO2020051541A1 (en) 2018-09-07 2020-03-12 Duke University Nanoparticulate drug delivery systems
DK3864163T3 (da) 2018-10-09 2024-05-06 Univ British Columbia Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
US12534435B2 (en) * 2020-03-27 2026-01-27 Generation Bio Co. Lipids and nanoparticle compositions thereof
MX2023012369A (es) 2021-04-20 2024-01-08 Generation Bio Co Lípidos catiónicos y composiciones de estos.
CA3215963A1 (en) * 2021-05-28 2022-12-01 Yaoxin LIN Lipid compound and use thereof in delivery of nucleic acid
EP4422605A4 (en) * 2021-10-25 2025-06-18 Duke University Poegma-based lipid nanoparticles
US20250213478A1 (en) * 2022-03-28 2025-07-03 Nof Corporation Cationic lipid having disulfide bond, lipid membrane structure including same, nucleic acid introduction agent and pharmaceutical composition containing any one of same, method for introducing nucleic acid into cell or target cell, and method for producing cellular pharmaceutical
CN114685784B (zh) * 2022-04-26 2023-09-15 北京清科胜因生物科技有限公司 一种用于核酸递送的聚(2-噁唑啉)脂质与脂质纳米颗粒及应用
WO2023239756A1 (en) * 2022-06-07 2023-12-14 Generation Bio Co. Lipid nanoparticle compositions and uses thereof
CN115105584B (zh) * 2022-06-28 2023-03-31 长春生物制品研究所有限责任公司 一种卡式瓶多剂量笔式注射组合包装的干扰素注射液
WO2024037577A1 (en) * 2022-08-18 2024-02-22 Suzhou Abogen Biosciences Co., Ltd. Composition of lipid nanoparticles
CN120112275A (zh) * 2022-08-25 2025-06-06 俄亥俄州创新基金会 用于递送包括核酸的活性剂的组合物和方法
US20240150306A1 (en) * 2022-09-27 2024-05-09 Reinvigoron Theratech, Inc. Compounds with cleavable disulfide moieties
JP2025535566A (ja) * 2022-11-08 2025-10-24 サムヤン ホールディングス コーポレイション カチオン性脂質及びその製造方法
EP4626402A1 (en) 2022-12-01 2025-10-08 Generation Bio Co. Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
EP4704855A1 (en) * 2023-04-26 2026-03-11 Saliogen Therapeutics, Inc. Lipid nanoparticle (lnp) formulations
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025043146A2 (en) * 2023-08-24 2025-02-27 Molecular Axiom Inc. Lipid nanoparticle compositions and methods of using same
WO2025064850A1 (en) 2023-09-22 2025-03-27 BioNTech SE Rna constructs with n-terminal degrons to enhance an immune response
FR3155424A1 (fr) 2023-11-15 2025-05-23 BioNTech SE Compositions immunogènes contre le sars-cov-2
WO2025106754A1 (en) 2023-11-15 2025-05-22 BioNTech SE Coronavirus vaccine
WO2025149492A1 (en) 2024-01-08 2025-07-17 BioNTech SE Rna encoding an immune inhibitory il-1 family member
WO2025166238A1 (en) * 2024-01-31 2025-08-07 Orna Therapeutics, Inc. Fast-shedding polyethylene glycol lipids
WO2025178465A1 (ko) * 2024-02-19 2025-08-28 주식회사 메디치바이오 신규한 이온화 지질 및 이를 이용한 지질 나노입자 조성물
WO2025230906A1 (en) * 2024-04-29 2025-11-06 Saliogen Therapeutics, Inc. Lipid nanoparticle (lnp) formulations
WO2025237830A1 (en) * 2024-05-15 2025-11-20 Evonik Operations Gmbh Polyoxyalkylene-1,2-di(alkyloxy)propanoxy-carbonylaminopropyl compounds, wherein the polyoxyalkylene is a poly(ethylene oxide) having c1 to c3-alkyloxymethyl side chains
WO2025255027A1 (en) * 2024-06-03 2025-12-11 Flagship Labs 114, Inc. Lipid nanoparticles for topical delivery
WO2026047603A1 (en) 2024-08-28 2026-03-05 BioNTech SE Sars-cov-2 immunogenic compositions
WO2026057626A1 (en) 2024-09-11 2026-03-19 BioNTech SE Peptidoglycan hydrolases having multiple enzymatically active domains
WO2026057625A1 (en) 2024-09-11 2026-03-19 BioNTech SE Peptidoglycan hydrolases having a chap domain with engineered active site
WO2026068864A1 (en) 2024-09-30 2026-04-02 BioNTech SE Engineered ch1 and cl domains for the prevention of chain mispairing
WO2026082899A2 (en) 2024-10-16 2026-04-23 BioNTech SE Rna for preventing or treating tuberculosis
WO2026090590A1 (en) * 2024-10-25 2026-04-30 Remedium Bio, Inc. Nanoparticle formulations for the delivery of dna to adipose tissue
WO2026119817A1 (en) 2024-12-02 2026-06-11 BioNTech SE Agents and methods for targeted delivery of immune effector cells
WO2026125598A1 (en) 2024-12-13 2026-06-18 BioNTech SE Measuring nucleic acid integrity
WO2026125590A1 (en) 2024-12-13 2026-06-18 BioNTech SE Measuring nucleic acid integrity
WO2026148356A1 (en) 2025-01-06 2026-07-09 BioNTech SE Coronavirus and influenza immunogenic combinations
WO2026150132A1 (en) 2025-01-12 2026-07-16 BioNTech SE Combination therapy comprising an rna cancer vaccine and a multispecific binding agent targeting pd-1/pd-l1 and vegf/vegfr for cancer treatment
WO2026162682A1 (en) 2025-01-29 2026-08-06 BioNTech SE Compositions for delivery of plasmodium rh5 antigens and related methods
WO2026162552A1 (en) 2025-01-31 2026-08-06 BioNTech SE Agents and methods for targeted delivery to cells
CN121421963B (zh) * 2026-01-04 2026-05-05 广州隽沐生物科技股份有限公司 一种用于难溶性活性经皮黏膜给药的装配材料及制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013073480A1 (ja) * 2011-11-18 2013-05-23 日油株式会社 細胞内動態を改善したカチオン性脂質
WO2017061150A1 (ja) * 2015-10-08 2017-04-13 日油株式会社 O/w型エマルション
WO2019051289A1 (en) * 2017-09-08 2019-03-14 Generation Bio Co. FORMULATIONS OF LIPID NANOPARTICLES OF NON-VIRAL CAPSID-FREE DNA VECTORS
WO2019188867A1 (ja) * 2018-03-27 2019-10-03 日油株式会社 細胞内動態を改善した新規カチオン性脂質
JP2022546597A (ja) * 2019-09-06 2022-11-04 ジェネレーション バイオ カンパニー 閉端dnaおよび切断可能脂質を含む脂質ナノ粒子組成物ならびにそれらの使用方法
JP2023502576A (ja) * 2019-11-22 2023-01-25 ジェネレーション バイオ カンパニー イオン化可能な脂質およびそれらのナノ粒子組成物
JP2023518985A (ja) * 2020-03-27 2023-05-09 ジェネレーション バイオ カンパニー 新規脂質及びそれらのナノ粒子組成物
JP2023527747A (ja) * 2020-05-18 2023-06-30 ジェネレーション バイオ カンパニー 新規脂質及びそれらのナノ粒子組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008103276A2 (en) * 2007-02-16 2008-08-28 Merck & Co., Inc. Compositions and methods for potentiated activity of biologicaly active molecules
HK1206644A1 (en) * 2012-03-29 2016-01-15 Shire Human Genetic Therapies, Inc. Lipid-derived neutral nanoparticles
HRP20220156T1 (hr) * 2015-09-17 2022-04-15 Modernatx, Inc. Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
US11410746B2 (en) * 2016-04-27 2022-08-09 Massachusetts Institute Of Technology Stable nanoscale nucleic acid assemblies and methods thereof
EP3538067A1 (en) * 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013073480A1 (ja) * 2011-11-18 2013-05-23 日油株式会社 細胞内動態を改善したカチオン性脂質
WO2017061150A1 (ja) * 2015-10-08 2017-04-13 日油株式会社 O/w型エマルション
WO2019051289A1 (en) * 2017-09-08 2019-03-14 Generation Bio Co. FORMULATIONS OF LIPID NANOPARTICLES OF NON-VIRAL CAPSID-FREE DNA VECTORS
WO2019188867A1 (ja) * 2018-03-27 2019-10-03 日油株式会社 細胞内動態を改善した新規カチオン性脂質
JP2022546597A (ja) * 2019-09-06 2022-11-04 ジェネレーション バイオ カンパニー 閉端dnaおよび切断可能脂質を含む脂質ナノ粒子組成物ならびにそれらの使用方法
JP2023502576A (ja) * 2019-11-22 2023-01-25 ジェネレーション バイオ カンパニー イオン化可能な脂質およびそれらのナノ粒子組成物
JP2023518985A (ja) * 2020-03-27 2023-05-09 ジェネレーション バイオ カンパニー 新規脂質及びそれらのナノ粒子組成物
JP2023527747A (ja) * 2020-05-18 2023-06-30 ジェネレーション バイオ カンパニー 新規脂質及びそれらのナノ粒子組成物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JAIN, PRIYESH ET AL.: ""Zwitterionic Hydrogels Based on a Degradable Disulfide Carboxybetaine Cross-Linker"", LANGMUIR, vol. 35, no. 5, JPN6025015115, 2019, pages 1864 - 1871, ISSN: 0005874543 *
PLOS ONE, vol. vol. 12(11), JPN6026022476, 28 November 2017 (2017-11-28), pages 0187962, ISSN: 0005874544 *
TANAKA, HIROKI ET AL.: ""In Vivo Introduction of mRNA Encapsulated in Lipid Nanoparticles to Brain Neuronal Cells and Astro", MOLECULAR PHARMACEUTICS, vol. 15, no. 5, JPN6025015120, 2018, pages 2060 - 2067, ISSN: 0005874542 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024522692A (ja) * 2021-06-14 2024-06-21 ジェネレーション バイオ カンパニー カチオン性脂質及びその組成物
JP2024538582A (ja) * 2021-09-28 2024-10-23 セキラス インコーポレイテッド イオン化可能なカチオン性化合物

Also Published As

Publication number Publication date
EP4181948A4 (en) 2024-12-04
US20230320993A1 (en) 2023-10-12
AU2021307952A1 (en) 2023-03-02
WO2022016089A3 (en) 2022-03-03
MX2023000806A (es) 2023-04-11
WO2022016089A2 (en) 2022-01-20
KR20230052895A (ko) 2023-04-20
IL299896A (en) 2023-03-01
EP4181948A2 (en) 2023-05-24
CA3186033A1 (en) 2022-01-20
CN116437964A (zh) 2023-07-14
JP2026074198A (ja) 2026-05-01

Similar Documents

Publication Publication Date Title
US20230320993A1 (en) Methods for encapsulating polynucleotides into reduced sizes of lipid nanoparticles and novel formulation thereof
US12252470B2 (en) Lipids and nanoparticle compositions thereof
US20220370357A1 (en) Ionizable lipids and nanoparticle compositions thereof
US12263228B2 (en) Lipids and compositions thereof
EP4351533A1 (en) Apoe and apob modified lipid nanoparticle compositions and uses thereof
US20240293574A1 (en) Cationic lipids and compositions thereof
US20230181764A1 (en) Novel lipids and nanoparticle compositions thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260602